It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Onchocerciasis is a parasitic disease with high socio-economic burden particularly in sub-Saharan Africa. The elimination plan for this disease has faced numerous challenges. A multi-epitope prophylactic/therapeutic vaccine targeting the infective L3 and microfilaria stages of the parasite’s life cycle would be invaluable to achieve the current elimination goal. There are several observations that make the possibility of developing a vaccine against this disease likely. For example, despite being exposed to high transmission rates of infection, 1 to 5% of people have no clinical manifestations of the disease and are thus considered as putatively immune individuals. An immuno-informatics approach was applied to design a filarial multi-epitope subunit vaccine peptide consisting of linear B-cell and T-cell epitopes of proteins reported to be potential novel vaccine candidates. Conservation of the selected proteins and predicted epitopes in other parasitic nematode species suggests that the generated chimera could be helpful for cross-protection. The 3D structure was predicted, refined, and validated using bioinformatics tools. Protein-protein docking of the chimeric vaccine peptide with the TLR4 protein predicted efficient binding. Immune simulation predicted significantly high levels of IgG1, T-helper, T-cytotoxic cells, INF-γ, and IL-2. Overall, the constructed recombinant putative peptide demonstrated antigenicity superior to current vaccine candidates.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 IBMM, Université Libre de Bruxelles, Department of Molecular Biology, Institute of Biology and Molecular Medicine, Gosselies, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746); Faculty of Science, University of Buea, Department of Biochemistry and Molecular Biology, Buea, Cameroon (GRID:grid.29273.3d) (ISNI:0000 0001 2288 3199)
2 Faculty of Science, University of Buea, Department of Biochemistry and Molecular Biology, Buea, Cameroon (GRID:grid.29273.3d) (ISNI:0000 0001 2288 3199)
3 Jomo Kenyatta University of Agriculture and Technology, Department of Biochemistry, Faculty of Science, Juja, Kenya (GRID:grid.411943.a) (ISNI:0000 0000 9146 7108)
4 University of Buea, Department of Microbiology and Parasitology, Faculty of Science, Buea, Cameroon (GRID:grid.29273.3d) (ISNI:0000 0001 2288 3199)
5 University of Buea, Department of Public Health and Hygiene, Faculty of Health Science, Buea, Cameroon (GRID:grid.29273.3d) (ISNI:0000 0001 2288 3199)
6 IBMM, Université Libre de Bruxelles, Department of Molecular Biology, Institute of Biology and Molecular Medicine, Gosselies, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)